The reverse split will mechanically boost the ADS price, but the underlying equity value is unchanged. Monitor the stock's post-split price action for potential selling pressure and Nasdaq compliance confirmation. The company's multiple shelf registrations suggest possible future dilution risk.
Price Chart
Executive Summary
Trinity Biotech announced a mandatory ADS ratio change from 1 ADS representing 20 Class A ordinary shares to 1 ADS representing 600 Class A ordinary shares, effective July 24, 2026. This is effectively a 1-for-30 reverse ADS split intended to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The filing does not alter the company's underlying ordinary shares or fundamentals.
Key Facts
- ADS ratio changes from 1:20 to 1:600 (effective 1-for-30 reverse split) on July 24, 2026.
- Every 30 old ADSs will be mandatorily exchanged for 1 new ADS; no fractional shares issued.
- Purpose is to regain Nasdaq $1.00 minimum bid price compliance and attract broader investors.
- No change to Class A ordinary shares; ADS continues trading under symbol TRIB.
- Company cannot guarantee post-split price will be 30x pre-split price.
Financial Impact
No financial figures reported; reverse split mechanically increases ADS price ~30x but does not change market cap or fundamentals.
Risk Factors
- Failure to maintain $1.00 bid price post-split could lead to delisting.
- Reverse splits often attract short-term selling pressure from retail holders.
- Multiple outstanding shelf registrations indicate potential future equity dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001554855-26-001607 |
| Exhibit: ex991_1.htm | 0001554855-26-001607 |
| Document: 0001554855-26-001607-index-headers.html | 0001554855-26-001607 |
| Document: 0001554855-26-001607-index.html | 0001554855-26-001607 |
| Document: 0001554855-26-001607.txt | 0001554855-26-001607 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | 6-K | $5.77 | awaiting T+60 | — | $7.15 (+23.92%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.15 (−10.62%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.15 (−25.52%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.15 (+27.56%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.15 (−32.55%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.15 (−35.99%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.15 (−38.73%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.15 (+2257.40%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.15 (+2257.40%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.15 (+1799.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers